Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LF, UK.
Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Pharmacoeconomics. 2021 Dec;39(12):1443-1454. doi: 10.1007/s40273-021-01067-w. Epub 2021 Aug 19.
Decisions on funding new healthcare technologies assume that all health improvements are valued equally. However, public reaction to health technology assessment (HTA) decisions suggests there are health attributes that matter deeply to them but are not currently accounted for in the assessment process. We aimed to determine the relative importance of attributes of illness that influence the value placed on alleviating that illness.
We conducted a discrete choice experiment survey that presented general public respondents with 15 funding decisions between hypothetical health conditions. The conditions were defined by five attributes that characterise serious illnesses, plus the health gain from treatment. Respondent preferences were modelled using conditional logistic regression and latent class analysis.
905 members of the UK public completed the survey in November 2017. Respondents generally preferred to provide treatments for conditions with 'better' characteristics. The exception was treatment availability, where respondents preferred to provide treatments for conditions where there is no current treatment, and were prepared to accept lower overall health gain to do so. A subgroup of respondents preferred to prioritise 'worse' health states.
This study suggests a preference among the UK public for treating an unmet need; however, it does not suggest a preference for prioritising other distressing aspects of health conditions, such as limited life expectancy, or where patients are reliant on care. Our results are not consistent with the features currently prioritised in UK HTA processes, and the preference heterogeneity we identify presents a major challenge for developing broadly acceptable policy.
新医疗技术的资金决策假设所有健康改善都具有同等价值。然而,公众对健康技术评估(HTA)决策的反应表明,存在一些对他们来说非常重要的健康属性,但目前在评估过程中并未得到考虑。我们旨在确定影响人们对缓解疾病的价值评估的疾病属性的相对重要性。
我们进行了一项离散选择实验调查,向英国公众受访者展示了 15 项关于假设健康状况的资金决策。这些条件由五个特征严重疾病的属性和治疗带来的健康收益来定义。使用条件逻辑回归和潜在类别分析来对受访者的偏好进行建模。
2017 年 11 月,905 名英国公众完成了调查。受访者普遍更倾向于为具有“更好”特征的疾病提供治疗。例外的是治疗可及性,受访者更倾向于为当前尚无治疗方法的疾病提供治疗,并愿意接受较低的总体健康收益。有一小部分受访者更倾向于优先考虑“更差”的健康状况。
本研究表明,英国公众更倾向于治疗未满足的需求;然而,这并不意味着他们更倾向于优先考虑健康状况的其他令人痛苦的方面,如有限的预期寿命,或患者依赖护理的情况。我们的结果与英国 HTA 流程中目前优先考虑的特征不一致,我们确定的偏好异质性为制定广泛可接受的政策带来了重大挑战。